- Home
- » Tags
- » Moxetumomab pasudotox
Top View
- (INN) for Biological and Biotechnological Substances
- Statement on Future Research and Therapies For
- Hairy Cell Leukemia and COVID-19 Adaptation of Treatment Guidelines
- Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
- The Oncology Market for Antibody–Drug Conjugates
- 761104Orig1s000
- (PRIMO) Antibody-Drug Conjugate (ADC) Summit
- Antibody-Drug Conjugates in Clinical Trials for Lymphoid Malignancies and Multiple Myeloma Bo Yu1 and Delong Liu2,3*
- Role of Blinatumomab in Acute Lymphoblastic Leukemia
- Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox
- Profile of Polatuzumab Vedotin in the Treatment
- Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- Advances in Hematology & Oncology Volume 10, Issue 4 April 2012 April 4 Issue 10, Volume Oncology & Hematology in Advances Clinical
- Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens
- Moxetumomab Pasudotox
- Oncology Therapy for the Generalist
- ADC) That Overcomes Resistance to Auristatin Based Adcs
- View Volume 2 Issue 2
- Antibody-Based Immunotherapy
- PDF of Antibody News
- Services That Require Precertification Standard Precert Effective: 7/1/2021 This Applies to Elective, Nonemergency Services
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- The New Therapeutic Horizons for Acute Lymphoblastic Leukemia
- Lumoxiti, INN-Moxetumomab Pasudotox
- Medical Drug Prior Authorization List/External Posting Effective August 2021 Page 1 Last Updated 8/4/2021
- Medicare Part B PA List Effective 2021
- ATC Vet 2021 Atccode Atcdescription Atcdescriptionsi QA ALIMENTARY TRACT and METABOLISM ZDRAVILA ZA BOLEZNI PREBAVIL in PRESNOVE
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Low Grade Lymphoproliferative Disorders CLL , HCL , T-PLL) Adult Algorithm
- Antibody-Drug Conjugates: Simple Idea, Complicated Matter
- Prior Authorization — Premium
- Oncology and Chemo-Support Drug List
- Blinatumomab for the Treatment of Philadelphia Chromosome–Negative, Precursor B-Cell
- Crizanlizumab-Tmca
- “What's New” Medical Pharmaceutical Policy March
- (INN) for Biological and Biotechnological Substances
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Codes Drug Name J3262 Actemra
- New Drug Updates in Hematologic Malignancies Rebecca J
- Design and Efficacy of Antibody Drug Conjugates in Oncology
- BCBSMN Medicare
- BLOOD RESEARCH April 2021 ARTICLE
- 5-Azacytidine Prevents Relapse and Produces Long-Term Complete Remissions in Leukemia Xenografts Treated with Moxetumomab Pasudo
- Download Article (PDF)
- Conversations with Oncology Investigators Bridging the Gap Between Research and Patient Care
- Moxetumomab Pasudotox in Heavily Pre‑Treated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long‑Term Follow‑Up from the Pivotal Trial Robert J
- Phoenix Clinical Trials
- Recent Developments in Immunotherapy for Acute Lymphoblastic Leukemia
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- LUMOXITI, INN-Moxetumomab Pasudotox
- Antibodies to Watch in 2018